X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (24) 24
index medicus (21) 21
hematology (18) 18
animals (14) 14
human necessities (14) 14
hygiene (14) 14
medical or veterinary science (14) 14
preparations for medical, dental, or toilet purposes (14) 14
mice (13) 13
purines - pharmacology (13) 13
quinazolinones - pharmacology (13) 13
signal transduction - drug effects (11) 11
specific therapeutic activity of chemical compounds ormedicinal preparations (11) 11
activation (10) 10
apoptosis - drug effects (10) 10
abridged index medicus (9) 9
apoptosis (9) 9
cell line, tumor (9) 9
phosphatidylinositol 3-kinases - antagonists & inhibitors (9) 9
leukemia, lymphocytic, chronic, b-cell - drug therapy (8) 8
leukemia, lymphocytic, chronic, b-cell - pathology (8) 8
oncology (8) 8
article (7) 7
expression (7) 7
hemic and lymphatic diseases (7) 7
leukemia (7) 7
phosphorylation (7) 7
survival (7) 7
cell survival - drug effects (6) 6
lymphoid neoplasia (6) 6
phosphatidylinositol 3-kinases - metabolism (6) 6
analysis (5) 5
chemistry (5) 5
class ia phosphatidylinositol 3-kinase - antagonists & inhibitors (5) 5
enzyme inhibitors - pharmacology (5) 5
in-vivo (5) 5
lymphatic leukemia (5) 5
lymphoma (5) 5
metallurgy (5) 5
organic chemistry (5) 5
peptides (5) 5
pi3k (5) 5
antineoplastic agents - pharmacology (4) 4
antineoplastic agents - therapeutic use (4) 4
b-cells (4) 4
blotting, western (4) 4
cal-101 (4) 4
cancer (4) 4
cell biology (4) 4
cell proliferation (4) 4
cell proliferation - drug effects (4) 4
chronic lymphatic leukemia (4) 4
chronic lymphocytic-leukemia (4) 4
enzyme activation - drug effects (4) 4
enzyme-linked immunosorbent assay (4) 4
female (4) 4
gs-1101 (4) 4
inhibitors (4) 4
leukemia, lymphocytic, chronic, b-cell - genetics (4) 4
leukemia, lymphocytic, chronic, b-cell - metabolism (4) 4
pathway (4) 4
proliferation (4) 4
protein kinase inhibitors - pharmacology (4) 4
protein-tyrosine kinases - antagonists & inhibitors (4) 4
pyrazines - administration & dosage (4) 4
thrombopoietin - pharmacology (4) 4
tyrosine (4) 4
agammaglobulinaemia tyrosine kinase (3) 3
aged (3) 3
b-cell receptor (3) 3
benzamides - administration & dosage (3) 3
biochemistry & molecular biology (3) 3
bone marrow cells - drug effects (3) 3
bone marrow cells - pathology (3) 3
bruton's tyrosine kinase (3) 3
cdk4 (3) 3
cdk6 (3) 3
cell adhesion (3) 3
cell division - drug effects (3) 3
cell line (3) 3
cells (3) 3
cells, cultured (3) 3
class i phosphatidylinositol 3-kinases (3) 3
class ia phosphatidylinositol 3-kinase - genetics (3) 3
class ia phosphatidylinositol 3-kinase - metabolism (3) 3
cll (3) 3
disease models, animal (3) 3
dose-response relationship, drug (3) 3
drug synergism (3) 3
gene (3) 3
growth (3) 3
hematology, oncology and palliative medicine (3) 3
hematopoietic stem cells - cytology (3) 3
ibrutinib (3) 3
indoles - pharmacology (3) 3
lymphomas (3) 3
male (3) 3
mantle cell lymphoma (3) 3
megakaryocytes - cytology (3) 3
mice, inbred c57bl (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 323 - 332
Acalabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase with greater specificity for the enzyme than the first-in-class agent, ibrutinib. It had... 
B-CELL RECEPTOR | MEDICINE, GENERAL & INTERNAL | ACTIVATION | IN-VIVO | X-LINKED AGAMMAGLOBULINEMIA | IBRUTINIB | BTK | PCI-32765 | TYROSINE KINASE INHIBITOR | LYMPHOMA | OPEN-LABEL | Recurrence | Benzamides - pharmacokinetics | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Benzamides - adverse effects | Headache - chemically induced | Chromosome Deletion | Protein Kinase Inhibitors - pharmacokinetics | Administration, Oral | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Agammaglobulinaemia Tyrosine Kinase | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Treatment outcome | Usage | Care and treatment | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Pharmacology | Dosage and administration | Pharmacokinetics | Antineoplastic agents | Tyrosine | Headache | Pharmacodynamics | Transformation | Chronic lymphatic leukemia | Inhibitor drugs | Leukemia | Diarrhea | Chromosome deletion | Lymphatic leukemia | Kinases | Lymphoma | Bruton's tyrosine kinase | Patients | Clonal deletion | Lymphomas | Safety | Drug therapy | Lymphocytosis | Protein-tyrosine kinase | Chromosome 17 | Index Medicus | Abridged Index Medicus
Journal Article
Blood, ISSN 0006-4971, 01/2011, Volume 117, Issue 2, pp. 591 - 594
Phosphatidylinositol-3-kinase p110 delta serves as a central integration point for signaling from cell surface receptors known to promote malignant B-cell... 
PHOSPHOINOSITIDE 3-KINASE P110-DELTA | HEMATOLOGY | ANTIGEN RECEPTOR | Lymphoid Neoplasia | Brief Report
Journal Article
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2012, Volume 120, Issue 21, pp. 3714 - 3714
Abstract Abstract 3714 Pre-clinical studies demonstrated the potential therapeutic value of targeting the PI3K Delta (PI3Kδ) pathway in lymphoma. A selective... 
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 21, pp. 4065 - 4065
Abstract Background Myelofibrosis (MF) is characterized by activation of the JAK-STAT pathway, with the JAK2 V617F mutation found in 50-60% of patients.... 
Journal Article
Acta Haematologica, ISSN 0001-5792, 2014, Volume 131, Issue 4, pp. 218 - 219
Journal Article
Blood, ISSN 0006-4971, 05/2014, Volume 123, Issue 22, pp. 3390 - 3397
Journal Article
Cell Cycle, ISSN 1538-4101, 06/2013, Volume 12, Issue 12, pp. 1892 - 1900
Phosphatidylinositol-3-kinase (PI3K) signaling is constitutive in most human cancers. Selective inhibition of PI3Kδ (p110δ) by GS-1101 has emerged as a... 
CDK6 | PIK3IP1 | CDK4 | mantle cell lymphoma | PI3Kα | PI3Kδ | PD 0332991 | GS-1101
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2013, Volume 8, Issue 12, p. e83830
CLL cell trafficking between blood and tissue compartments is an integral part of the disease process. Idelalisib, a phosphoinositide 3-kinase delta (PI3K... 
B-CELLS | SURVIVAL | MIGRATION | APOPTOSIS | CAL-101 | MICROENVIRONMENT | MULTIDISCIPLINARY SCIENCES | MOLECULE-1 | TYROSINE KINASE INHIBITOR | RECEPTOR | EXPRESSION | Cell Survival - drug effects | Integrin alpha4beta1 - metabolism | Purines - pharmacology | Stromal Cells - pathology | Bone Marrow Cells - pathology | Enzyme Inhibitors - pharmacology | Cell Adhesion - drug effects | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Integrins - metabolism | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Animals | Signal Transduction - drug effects | Stromal Cells - drug effects | Cell Line, Tumor | Mice | Gene Expression Regulation, Neoplastic - drug effects | Endothelial Cells - pathology | Vascular Cell Adhesion Molecule-1 - metabolism | Quinazolinones - pharmacology | Endothelial Cells - drug effects | B cells | Analysis | Integrins | Endothelium | Cell culture | Vascular cell adhesion molecule 1 | Phosphorylation | Pathogenesis | Leukemia | Shear flow | Trafficking | AKT protein | Kinases | Tissues | VLA-4 antigen | Blood | Lymph nodes | Cell adhesion & migration | Atrophy | Cell growth | Immunology | Lymphocytes | Compartments | Cell adhesion | Bone marrow | Inhibition | Antigens | Chronic lymphatic leukemia | CD49d antigen | Hematology | Internal medicine | Shrinkage | Lymphatic leukemia | Tumor necrosis factor-α | Adhesion | 1-Phosphatidylinositol 3-kinase | Inhibitors | Stromal cells | Lymphomas | Lymphocytosis | Binding sites | Chemokines | Apoptosis | Cancer
Journal Article
Blood, ISSN 0006-4971, 11/2012, Volume 120, Issue 21, pp. 3876 - 3876
Abstract Abstract 3876 Background: Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western World and remains incurable with standard... 
Journal Article
Blood, ISSN 0006-4971, 10/2012, Volume 120, Issue 17, pp. 3501 - 3509
Stroma induces treatment resistance in chronic lymphocytic leukemia (CLL), possibly because of alterations in the BCL-2 family of proteins, which are key... 
B-CELLS | SURVIVAL | CAL-101 | DISEASE | SIGNALS | CXCR4 | MECHANISMS | CHEMOKINE RECEPTORS | INHIBITOR | HEMATOLOGY | EXPRESSION | Cell Communication - immunology | Lymph Nodes - pathology | Apoptosis - drug effects | Stromal Cells - pathology | Antibodies, Anti-Idiotypic - pharmacology | Coculture Techniques | Humans | Peptide Fragments - pharmacology | Mitochondria - immunology | Phosphatidylinositol 3-Kinases - metabolism | Membrane Potential, Mitochondrial - drug effects | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Immunoglobulin M - immunology | Signal Transduction - immunology | Lymphocytes - immunology | Stromal Cells - drug effects | Bone Marrow Cells - drug effects | Lymph Nodes - drug effects | Tumor Cells, Cultured | Leukemia, Lymphocytic, Chronic, B-Cell - immunology | Quinazolinones - pharmacology | Proto-Oncogene Proteins - pharmacology | Purines - pharmacology | Bone Marrow Cells - pathology | Stromal Cells - immunology | Mitochondria - metabolism | Mitochondria - drug effects | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Lymphocytes - pathology | Apoptosis - immunology | Membrane Potential, Mitochondrial - immunology | Signal Transduction - drug effects | Chemokine CXCL12 - pharmacology | Leukemia, Lymphocytic, Chronic, B-Cell - metabolism | Lymphocytes - drug effects | Cell Communication - drug effects | Lymphoid Neoplasia
Journal Article
Blood, ISSN 0006-4971, 11/2011, Volume 118, Issue 21, pp. 974 - 974
Abstract 974 We and others have previously found that CLL cells exposed to stroma are resistant to a wide variety of treatments. While this phenomenon is... 
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 06/2017, Volume 23, Issue 11, pp. 2831 - 2841
Journal Article
Blood, ISSN 0006-4971, 11/2012, Volume 120, Issue 21, pp. 791 - 791
Abstract Abstract 791 The phosphatidylinositol-3-kinase (PI3K) signaling pathway is constitutively activated at a high frequency in human cancer. As the first... 
Journal Article